use of p63 in assessing mimics of prostatic adenocarcinoma
DESCRIPTION
Use of p63 in assessing mimics of prostatic adenocarcinoma. DR. A. T. ATANDA, BAYERO UNIVERSITY/AMINU KANO TEACHING HOSP. KANO. BACKGROUND. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/1.jpg)
USE OF P63 IN ASSESSING MIMICS OF PROSTATIC ADENOCARCINOMADR. A. T. ATANDA, BAYERO UNIVERSITY/AMINU KANO TEACHING HOSP.KANO
![Page 2: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/2.jpg)
BACKGROUND
Prostatic carcinoma has several well documented mimics, particularly on core needle biopsy, for which the pathologist cannot rely on morphology alone for their differential diagnosis.
Correct evaluation of these mimics will help prevent unnecessary treatment for cancer.
![Page 3: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/3.jpg)
Mimics of Prostatic Carcinoma
AtrophyBasal Cell HyperplasiaAdenosisSeminal vesiclesGangliaParaganglia
![Page 4: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/4.jpg)
![Page 5: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/5.jpg)
AIM
To evaluate the reliability of morphology alone measured against immunohistochemistry in evaluating equivocal prostatic biopsies.
![Page 6: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/6.jpg)
METHODOLOGY
p63 immunohistochemical stain (clone BC4A4)
equivocal impressions of benign versus malignant diagnoses over a
12-month period (Jan – Dec., 2013)
Negative stain = positive for malignancy
Positive stain = negative for malignancy
![Page 7: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/7.jpg)
Criteria for diagnosis of CaP
Major criteria infiltrative acini which may have
cribriform dispositionabsence of basal cells; and nuclear and/or nucleolar
enlargement. Minor criteria included: adjacent high grade PIN and nuclear hyperchromasia
others mucinous fibroplasia, perineural
invasion and glomerulations
![Page 8: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/8.jpg)
Results61 cases of CaP27(44.3%) were considered
equivocal. 6 (22.2%) of the 27 showed
basal cell staining 3 cases of atrophy basal cell hyperplasia clear cell cribriform
hyperplasiaUrothelium
![Page 9: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/9.jpg)
Results
The probability of erroneous interpretation ranged btw 8.7% and 42.3%
PPV of morphology alone was 77.8%.
![Page 10: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/10.jpg)
RESULT ctdSensitivity of 100% (83.8% to 100%);
Specificity of 77.8% (57.7% to 91.3%);
NPV of 100%.
![Page 11: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/11.jpg)
![Page 12: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/12.jpg)
![Page 13: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/13.jpg)
![Page 14: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/14.jpg)
![Page 15: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/15.jpg)
Discussion Our study 22.2% reclassified; Error rate
8.7% (sensitivity:77.8%; specificity: 100%)
7.5% error rate reported by Berney et at1 (London)
1.3% documented by Epstein et al2 in the US
100% and 64%.3
![Page 16: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/16.jpg)
Reasons for lower specificity by morphologySurgeons
Sample adequacy (volume & number)
Crush artifacts Cauterization artifacts
Pathologists Good sections inexperience
![Page 17: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/17.jpg)
Discussion
The use of immunohistochemical staining for p63
protein alone, or as a component of a cocktail
comprising p63, alpha-methyl-CoA-racemase
(AMACR) and Cytokeratin CK903,3 is also gaining
momentum.
![Page 18: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/18.jpg)
conclusionFor improvement in diagnosis of carcinoma of prostate, particularly from core needle biopsies, there is need for pathologists to pay attention to the common mimics of carcinoma and incorporate immunohistochemistry into their diagnostic armamentarium.
![Page 19: Use of p63 in assessing mimics of prostatic adenocarcinoma](https://reader036.vdocuments.site/reader036/viewer/2022062314/56812bb4550346895d8ff583/html5/thumbnails/19.jpg)
1. Berney DM, Fisher G, Kattan MW, Oliver RT, Møller H, Fearn P, et al; Trans-Atlantic
prostate group. Pitfalls in the diagnosis of prostatic cancer: retrospective review of 1791 cases
with clinical outcome. Histopathology 2007; 51: 452-7.
2. Epstein JI, Walsh PC, Sanfilippo F. Clinical and cost impact of second-opinion pathology:
review of prostate biopsies prior to radical prostatectomy. Am J Surg Pathol 1996; 20: 851-7.
3. Tokumaru Y, Harden S V, Sun D I, Yamashita K, Epstein J I, Sidransky D. Optimal use of a
panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate
adenocarcinoma. Clin Cancer Res 2004; 10: 5518-22.
References
z